Archive: 20/08/2015

Afatinib: Added benefit in certain mutations confirmed

Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have ...

page 5 from 10